0.9622281740	hemolytic anemia
0.9607812304	calcium chloride
0.9602478094	visual field
0.9585169880	folic acid
0.9583700431	uric acid
0.9571628031	myocardial infarction
0.9478224545	diabetic nephropathy
0.9469818422	status epilepticus
0.9463432118	spinal cord
0.9431204429	breast cancer
0.9415796273	neuroleptic malignant syndrome
0.9415332759	oxidative stress
0.9326109017	heart failure
0.9284477039	rheumatoid arthritis
0.9283333680	nephrotic syndrome
0.9238407429	qt interval
0.9210413626	renal failure
0.9207073537	acute liver failure
0.9194264960	blood pressure
0.9169773162	bone marrow
0.9154217551	heart rate
0.9124112447	confidence interval
0.9117849768	acute renal failure
0.9058013270	ng ml
0.9030163080	mm hg
0.9001810738	nitric oxide
0.8879338666	vascular resistance
0.8866044336	cardiac arrest
0.8852330618	liver failure
0.8846498032	hemorrhagic cystitis
0.8792568623	coronary artery disease
0.8740380324	renal function
0.8726253995	puromycin aminonucleoside
0.8718692253	coronary artery
0.8698152369	receptor antagonist
0.8693924658	glyceryl trinitrate
0.8396099681	mg m2
0.8385780743	blood flow
0.8368659013	optic neuropathy
0.8328324513	combination therapy
0.8269794401	left ventricular
0.8240498954	case report
0.8191274285	micrograms kg
0.8167486572	life threatening
0.8148543638	adverse effects
0.8045034821	growth factor
0.7996385706	passive avoidance
0.7981472963	wistar rats
0.7915585794	high doses
0.7902213124	heart disease
0.7851137801	sprague dawley
0.7742029323	clinical trial
0.7716308185	myocardial ischemia
0.7634125125	double blind
0.7611075852	muscle rigidity
0.7427517830	body weight
0.7427151346	serotonin reuptake
0.7414510585	placebo controlled
0.7401142060	adenovirus disease
0.7384243834	long term
0.7345679014	l dopa
0.7332456396	mg per deciliter
0.7238978271	statistically significant
0.7213855465	intravenous ribavirin
0.7208146267	short term
0.7145307360	torsade de pointes
0.7133901144	serum creatinine
0.7127484425	severe adenovirus
0.7084523996	risk factors
0.7058112346	arterial pressure
0.7022057673	data suggest
0.7005927485	increased risk
0.6975442907	endometrial
0.6956826581	extrapyramidal
0.6956826581	general
0.6945339721	skin
0.6940448167	prostaglandin
0.6932254552	death
0.6928597353	adverse events
0.6925982467	glomerular
0.6925982467	thrombosis
0.6920870716	adenosine
0.6904670537	local
0.6889789504	anesthesia
0.6889164331	disorders
0.6876074675	superoxide
0.6871789291	trials
0.6863125962	atrial
0.6858680442	standard
0.6851425818	stroke
0.6832380007	adenovirus
0.6829954204	platelet
0.6826822798	white
0.6823163901	cystitis
0.6817509316	creatinine
0.6815585150	thrombocytopenia
0.6811935942	significant increase
0.6810172098	secondary
0.6806426467	cognitive
0.6806310779	physical
0.6803790071	cessation
0.6792193987	medical
0.6777519726	abdominal
0.6776073118	protective
0.6770863079	sprague dawley rats
0.6767625278	eye
0.6760389790	water
0.6751987015	anti
0.6751627763	sinus
0.6746701507	neuroleptic induced
0.6746592936	hypothesis
0.6742767688	state
0.6742494892	vitamin
0.6731683435	area
0.6728805049	systemic
0.6727979910	venous
0.6727157892	relative
0.6724983834	grade
0.6709515136	diabetic
0.6706937780	ratio
0.6705359234	small
0.6705164790	mitochondrial
0.6699549961	reaction
0.6696628998	testing
0.6692324980	hypersensitivity
0.6688862443	free
0.6687956465	biopsy
0.6687956465	hemorrhage
0.6684801536	resistance
0.6684801536	microscopy
0.6684333299	p450
0.6683854052	protein
0.6678274528	activities
0.6677837613	inflammatory
0.6672182312	basal
0.6670379621	antiarrhythmic
0.6670322004	diabetes
0.6667882805	primary
0.6667100884	internal
0.6665465191	acetylcholine
0.6660608900	mental
0.6660608900	depression
0.6650572389	hospital
0.6649723253	marrow
0.6646017667	significant differences
0.6645232140	pulmonary
0.6644346812	carboplatin
0.6636475461	headache
0.6635726701	procedure
0.6634655177	performance
0.6631958879	phase
0.6624926065	wistar
0.6624054609	cortex
0.6620141126	peripheral
0.6619232140	oxygen
0.6616858620	edema
0.6612764718	steroid
0.6612554436	prostate
0.6612554436	gene
0.6610503368	alcohol
0.6609186176	delayed
0.6608176484	essential
0.6608176484	fluid
0.6607917696	autoimmune
0.6607917696	estradiol
0.6605849204	virus
0.6605849204	states
0.6605119159	prospective study
0.6604671120	arrhythmias
0.6604071054	scale
0.6603498828	progressive
0.6600904551	tests
0.6598520644	abuse
0.6598437299	reverse
0.6598371037	anesthetic
0.6598371037	reactive
0.6597330507	urinary
0.6597280594	adverse effect
0.6595230265	iron
0.6595217359	fluoxetine
0.6593027099	examination
0.6589968834	anaesthesia
0.6589273294	dopamine
0.6583245424	microg kg
0.6583108709	molecular
0.6578903895	delivery
0.6573566401	metoprolol
0.6573215076	immune
0.6572353015	average
0.6569333180	carotid
0.6565938868	series
0.6564282831	drinking
0.6564252257	endothelial
0.6563558772	cisapride
0.6563558772	proteinuria
0.6563558772	verapamil
0.6563558772	repeated
0.6561609290	ribavirin
0.6560798586	involvement
0.6556971479	sexual
0.6554943536	life
0.6554793297	vivo
0.6553772101	amiodarone
0.6549764448	antigen
0.6548734209	comparison
0.6547710649	carcinoma
0.6547193587	disorder
0.6545929869	cb 3717
0.6543309900	density
0.6539825435	metabolic
0.6539825435	event
0.6538544446	angiotensin
0.6537076847	ischemia
0.6536316135	continuous
0.6532844948	occlusion
0.6531413245	e2
0.6530499665	nephropathy
0.6530133045	transplant
0.6528315741	inhibitors
0.6527043537	movement
0.6524297442	multiple
0.6524153348	man
0.6523181476	penicillamine
0.6520527082	microg 0.5 microl
0.6519658484	cyclophosphamide
0.6508535354	mass
0.6507901419	direct
0.6507827508	randomly
0.6505776669	dna
0.6504946287	naloxone
0.6504946287	initial
0.6504946287	conscious
0.6503495610	activated
0.6503414155	apomorphine
0.6503263266	temporal
0.6501126631	frequency
0.6499076179	specific
0.6498398661	injury
0.6496753759	reversible
0.6496277577	epilepsy
0.6495623226	experimental
0.6494428011	serotonin
0.6493211920	atrophy
0.6493211920	deprivation
0.6493211920	synthase
0.6489136987	short
0.6484113136	immediately
0.6484097559	end
0.6483972173	haloperidol
0.6481547022	animal
0.6481514226	convulsions
0.6479014968	cardiotoxicity
0.6477564896	subsequent
0.6477328047	transient
0.6476456354	degree
0.6475144771	sleep
0.6473516368	diazepam
0.6465407597	nonsteroidal
0.6463477577	ethambutol
0.6463375039	lithium
0.6460381887	blocker
0.6460257025	seizure
0.6459468868	norepinephrine
0.6457721847	selective
0.6454300698	enzyme
0.6453247077	warfarin
0.6448858173	levodopa
0.6446405847	antidepressant
0.6446405847	emergency
0.6445907255	widely
0.6445870056	median
0.6443023579	complete
0.6440166581	microl
0.6435613284	undergoing
0.6434548983	half
0.6430286339	receptor agonist
0.6428451798	arterial
0.6427765100	fatal
0.6425518301	management
0.6425428849	dyskinesia
0.6424774356	children
0.6423397029	sedation
0.6421854945	induction
0.6421276476	paclitaxel
0.6420911669	dysfunction
0.6420440252	activation
0.6420217257	tumors
0.6415035127	ifosfamide
0.6415035127	bupivacaine
0.6413388542	cardiovascular
0.6411393704	enhanced
0.6409912894	hepatotoxicity
0.6409111219	hypertension
0.6409108584	correlated
0.6408972220	food
0.6407533680	dexamethasone
0.6405270803	risperidone
0.6403141439	urine
0.6403084481	neurons
0.6403010088	lower
0.6401370922	neurotoxicity
0.6401030148	reserpine
0.6400916004	prevention
0.6397386362	channel
0.6396131384	spinal
0.6393764212	ketamine
0.6392037365	young
0.6389036549	output
0.6388386896	prolonged
0.6388070919	metabolism
0.6388070919	aspartate
0.6388070919	inhibitory
0.6386635622	necrosis
0.6386635622	pathways
0.6384879660	male
0.6382222854	high dose
0.6381859977	impaired
0.6380678680	beta
0.6378535470	factors
0.6378055680	recently
0.6377779497	light
0.6376994697	conventional
0.6373658245	conversion
0.6372422107	postoperative
0.6371915491	growth
0.6371749655	type
0.6369150524	doxorubicin
0.6368583978	steroids
0.6367834192	reports
0.6366081915	behavioral
0.6365132127	gentamicin
0.6360967581	hepatic
0.6359703459	sodium
0.6352784165	amphetamine
0.6350823385	assessment
0.6349153473	test
0.6348718317	malignant
0.6345871246	potential
0.6344534271	arrhythmia
0.6342922290	case reports
0.6340874974	models
0.6340678752	dexmedetomidine
0.6338491894	total
0.6337619965	safety
0.6335737899	aortic
0.6334987882	interaction
0.6331524377	lesions
0.6331411917	pain
0.6329107464	tumor
0.6328854959	hypertensive
0.6328147841	site
0.6328147841	opioid
0.6328147841	pathway
0.6328147841	subcutaneous
0.6325899552	measures
0.6324531167	myocardial
0.6322709605	muscular
0.6322709605	medulla
0.6322398103	agonist
0.6322315214	aim
0.6320626288	hemorrhagic
0.6318433867	association
0.6316919214	previous
0.6315728107	transplantation
0.6315688094	alterations
0.6314576761	receive
0.6312925618	amnesia
0.6312925618	binding
0.6307792504	volume
0.6307474910	nephrotoxicity
0.6305738393	hypotension
0.6304031551	hour
0.6300154000	injections
0.6300068156	hiv
0.6297197360	peak
0.6296086048	chest
0.6296086048	chain
0.6295670450	parkinson
0.6294803278	adrenergic
0.6291602019	common
0.6291246331	adriamycin
0.6288715370	pretreatment
0.6288373371	rise
0.6287685449	fenoldopam
0.6287685449	isoniazid
0.6285525686	elderly
0.6281323638	model
0.6279400184	angioedema
0.6279112797	aspirin
0.6278806301	formation
0.6278806301	mechanical
0.6278806301	intervals
0.6272998156	addition
0.6271515679	flow
0.6268183921	hr
0.6267951983	fetal
0.6267951983	captopril
0.6267951983	echocardiography
0.6267951983	production
0.6267951983	monitoring
0.6267951983	attenuated
0.6264937910	timolol
0.6261316612	cerebral
0.6261239339	hypokalemia
0.6261239339	caffeine
0.6261239339	pre
0.6259621242	daily
0.6256043994	oxytocin
0.6256043994	maximal
0.6255600865	nmda
0.6255497687	visual
0.6254837831	pilocarpine
0.6252281787	micrograms
0.6252127954	diuretic
0.6249193248	nephrotic
0.6248917794	nerve
0.6244303469	bilateral
0.6242037251	akathisia
0.6239837831	mild
0.6239600347	spontaneous
0.6238464114	similar
0.6236834264	heparin
0.6230810353	biochemical
0.6227730572	randomised
0.6224671578	implicated
0.6224671578	aware
0.6223061536	map
0.6222698075	tolerability
0.6219515620	trial
0.6213325513	rat
0.6213001312	metformin
0.6212547753	tolerance
0.6212412259	laboratory
0.6212266102	central
0.6211422273	severity
0.6210597454	brain
0.6210454112	ammonia
0.6209072334	oral
0.6207091940	status
0.6205646884	tomography
0.6205510396	ciprofloxacin
0.6205510396	methadone
0.6205510396	prolongation
0.6205510396	rapid
0.6205510396	parkinsonism
0.6203905002	earlier
0.6202551626	therapeutic
0.6199603350	defect
0.6199603350	hippocampal
0.6198558684	nephrotoxic
0.6196257175	qt
0.6194570796	ng
0.6188507463	odds
0.6187530555	design
0.6186401487	tamoxifen
0.6185080119	cardiomyopathy
0.6180459434	mesna
0.6180062967	lead
0.6178084572	signs
0.6174428994	relationship
0.6171775625	stimulation
0.6166567078	findings suggest
0.6163618502	evaluation
0.6161652256	prior
0.6161652256	events
0.6161468883	tolerated
0.6161340069	treated animals
0.6161091057	block
0.6157510858	method
0.6155674218	force
0.6151211056	human
0.6149797107	population
0.6149482820	analysis
0.6148779126	mg kg i.v
0.6148593203	double
0.6146356907	midazolam
0.6146114657	efficacy
0.6145558685	cocaine
0.6145218087	data
0.6145106969	increases
0.6144165336	multicenter
0.6141634988	kidney
0.6141197826	positive
0.6140939132	hallucinations
0.6140665862	inhibitor
0.6138379707	fraction
0.6138144605	anemia
0.6137114035	respiratory
0.6136521620	contrast
0.6134313351	quantitative
0.6133931567	ocular
0.6133931567	sensitivity
0.6133821849	additional
0.6132903978	myopathy
0.6132168137	findings
0.6131982709	tachycardia
0.6129064180	behavior
0.6128157867	ventricular
0.6127758383	muscle
0.6126989834	intravenous
0.6126690783	structural
0.6126690783	etoricoxib
0.6126437392	antagonist
0.6125415295	efficacy and safety
0.6123167656	diagnosis
0.6122580527	left
0.6122299984	surgery
0.6120606302	recent
0.6117454768	diltiazem
0.6117454768	experience
0.6117454768	post
0.6113415000	cortical
0.6112990679	enalapril
0.6111759003	mg kg
0.6111660946	desipramine
0.6111622176	epileptic
0.6111157715	melatonin
0.6111157715	subsequently
0.6111157715	methamphetamine
0.6111157715	symptomatic
0.6109465183	controlled trial
0.6108704866	iv
0.6102460871	mediated
0.6101584076	mortality
0.6100268564	mechanisms
0.6096644998	controlled
0.6095193409	vascular
0.6094129091	cancer
0.6092583695	vessels
0.6091957961	discontinuation
0.6091367934	bladder
0.6090218977	rigidity
0.6088564366	lovastatin
0.6088564366	dexrazoxane
0.6088564366	vancomycin
0.6088564366	topical
0.6088564366	sirolimus
0.6085643113	coronary
0.6084005656	based
0.6083291660	users
0.6081927935	exposure
0.6081739235	setting
0.6075175723	calcium
0.6072268076	catalepsy
0.6069032120	low
0.6059171391	level
0.6057716320	action
0.6054206975	suprofen
0.6054206975	dextran
0.6051411585	flumazenil
0.6047427748	reduced
0.6046855172	enflurane
0.6046855172	halothane
0.6046855172	cholestatic
0.6046855172	limiting
0.6046855172	detection
0.6046855172	brainstem
0.6046855172	minor
0.6046855172	experiments
0.6046855172	compound
0.6046855172	screening
0.6046855172	aggressive
0.6046855172	penicillin
0.6046855172	isoproterenol
0.6044642082	adverse
0.6044281228	concentrations
0.6043699960	ii
0.6043267754	concentration
0.6041745570	mm
0.6037835237	cholinergic
0.6037150101	metoclopramide
0.6037150101	cibenzoline
0.6037150101	hyperalgesia
0.6037129037	order
0.6036971203	assessed
0.6022637489	stress
0.6021305360	presented
0.6018856215	scopolamine
0.6015627290	factor
0.6015472027	mechanism
0.6011925594	liver
0.6010789799	paracetamol
0.6009590469	isoflurane
0.6009590469	hyperprolactinemia
0.6009590469	highly
0.6009590469	limited
0.6009337777	remifentanil
0.6009337777	gastrointestinal
0.6009299028	men
0.6008476343	moderate
0.6006644573	impairment
0.6006490362	exercise
0.6006490362	refractory
0.6006490362	toxicities
0.6006490362	tobramycin
0.6006490362	extensive
0.6006490362	open
0.6003460571	outcome
0.6001837513	failure
0.6001053470	acid
0.5999467964	measurements
0.5995115911	aggregation
0.5995115911	valsartan
0.5995115911	indomethacin
0.5995115911	hemoglobin
0.5995115911	myocarditis
0.5992515120	baseline
0.5991423496	field
0.5991307400	succinylcholine
0.5990823576	randomized
0.5987321853	approximately
0.5985922089	propranolol
0.5985922089	overdose
0.5985922089	cumulative
0.5983600353	simultaneously
0.5982991801	potassium
0.5979031596	ml
0.5978066684	dobutamine
0.5978066684	hiccups
0.5978066684	carbamazepine
0.5978066684	large
0.5978066684	underlying
0.5978066684	information
0.5978066684	initially
0.5978066684	latency
0.5975713156	significantly lower
0.5975334652	receptor
0.5972526531	observations
0.5971757031	animals
0.5970497228	bone
0.5968665545	single
0.5968266858	memory
0.5966206466	tubular
0.5965458459	cell
0.5962582734	greater
0.5959584598	higher
0.5958726545	produced
0.5956611672	apoptosis
0.5956611672	major
0.5954856752	neuropathy
0.5954268785	receiving
0.5953825158	main
0.5952916851	taking
0.5952916851	diet
0.5950519534	blood
0.5950074292	motor
0.5947131647	heart
0.5942165709	dynamic
0.5941697321	hepatitis
0.5937964528	review
0.5935602048	fluconazole
0.5935602048	heavy
0.5935602048	amisulpride
0.5935602048	sulindac
0.5935602048	hematologic
0.5935602048	persistent
0.5935602048	lethal
0.5935602048	deaths
0.5935602048	adjusted
0.5935602048	thromboembolism
0.5935602048	surgical
0.5935602048	influence
0.5934809530	characterized
0.5934809530	led
0.5934177355	current
0.5932210623	weight
0.5931861330	aura
0.5926055814	nicotine
0.5924986808	combined
0.5923908090	versus
0.5920939255	myoclonus
0.5919810449	adrenaline
0.5919788154	tacrolimus
0.5919788154	blockade
0.5916737148	striatum
0.5915868037	improvement
0.5915862083	important
0.5914069480	yohimbine
0.5914069480	late
0.5914069480	generally
0.5914069480	concomitant
0.5912940674	neurological
0.5912940674	altered
0.5910874278	reactions
0.5910874278	sustained
0.5910874278	clinically
0.5909635402	dependent
0.5909153951	change
0.5907519547	male rats
0.5906290543	high
0.5901605324	analgesic
0.5901605324	functional
0.5901605324	medications
0.5900168091	appears
0.5894552934	prospective
0.5892845244	electron
0.5892678109	ht
0.5890726188	severe
0.5890721924	bupropion
0.5888851382	pretreated
0.5888326011	tacrine
0.5888326011	hypoxia
0.5888079470	onset
0.5884803346	protection
0.5883275002	authors
0.5882585862	passive
0.5879022194	nrf2
0.5877658552	early
0.5876808048	tissue
0.5867823528	epinephrine
0.5866514611	involved
0.5865096102	increasing
0.5865096102	marked
0.5863279946	bradycardia
0.5863279946	potent
0.5861922903	case
0.5861431239	serum
0.5857313457	nsaids
0.5852028141	hormone
0.5852016988	history
0.5849655577	migraine
0.5848997632	consistent
0.5848997632	absence
0.5845893638	infusion
0.5844773105	syndrome
0.5841775647	incidence
0.5839813944	avoidance
0.5834474768	loss
0.5834326142	auditory
0.5833257238	oral administration
0.5830864274	interval
0.5823457197	chloride
0.5821410752	morphine
0.5815711563	drugs
0.5814720210	woman
0.5812670348	mg kg i.p
0.5811121016	nausea
0.5810293345	studied
0.5807457197	investigate
0.5805616161	response
0.5803928703	decrease
0.5803785173	evidence
0.5800790531	arthritis
0.5800319542	inhibition
0.5799208678	role
0.5797578498	caused
0.5793456037	cells
0.5790289100	duration
0.5782643373	solution
0.5782643373	antibody
0.5779220170	statistically
0.5770218068	dose dependent
0.5759865736	d2
0.5759683086	na
0.5758266195	ca
0.5756624131	artery
0.5755574306	occurred
0.5755461616	occurrence
0.5754401651	expression
0.5753943172	pressure
0.5744889772	chronic
0.5744332822	m2
0.5742893519	microg
0.5739610354	amb
0.5735527786	body
0.5734677403	plasma
0.5730518754	word
0.5729621700	decreases
0.5729441787	methylprednisolone
0.5726306211	words
0.5719434236	damage
0.5719216621	background
0.5716714700	complications
0.5716254431	aminonucleoside
0.5715301025	i.p
0.5712782486	significant
0.5708012756	delirium
0.5708012756	isolated
0.5708012756	proliferation
0.5708012756	learning
0.5708012756	hydrochloride
0.5708012756	ouabain
0.5708012756	supplementation
0.5708012756	pressor
0.5708012756	neuronal
0.5708012756	infants
0.5707084213	infection
0.5707084213	prevent
0.5707084213	safe
0.5707084213	complication
0.5706772908	induces
0.5706772908	continued
0.5706772908	resulting
0.5706772908	required
0.5706772908	analyzed
0.5706772908	psychosis
0.5706772908	antagonists
0.5706772908	adrenoceptor
0.5705843401	ip
0.5704214700	chemotherapy
0.5702926690	da
0.5700759252	suppressed
0.5698992459	differences
0.5696957678	task
0.5696957678	db
0.5695796449	drug
0.5694626853	suggest
0.5691378540	symptoms
0.5690577636	literature
0.5684197079	azt
0.5676953584	mrna
0.5674323658	enac
0.5673991364	acute
0.5673607315	effective
0.5673001089	women
0.5670536690	pattern
0.5670369175	accumulation
0.5670307018	objective
0.5669534933	optic
0.5664392026	acetaminophen
0.5655402174	conduction
0.5655402174	diastolic
0.5655402174	correlation
0.5655402174	died
0.5655402174	release
0.5654642218	coma
0.5654642218	recipients
0.5654642218	vasculitis
0.5654642218	suggesting
0.5654642218	produce
0.5654642218	subject
0.5654642218	rapidly
0.5654642218	diagnosed
0.5654642218	enzymes
0.5654642218	occurring
0.5654642218	reduce
0.5654642218	possibly
0.5654642218	hyperactivity
0.5654642218	extent
0.5654642218	intensity
0.5653983457	uveitis
0.5653983457	overflow
0.5653983457	dl
0.5653983457	deficits
0.5653983457	interferon
0.5653983457	channels
0.5653983457	count
0.5653983457	highest
0.5652303383	adult
0.5651943767	elevated
0.5650765169	i.v
0.5649677720	cross
0.5649677720	tremor
0.5649677720	iohexol
0.5649677720	scores
0.5649477691	resulted
0.5647079944	degeneration
0.5647043204	condition
0.5647043204	comparable
0.5647043204	reduces
0.5647043204	recovery
0.5647043204	prazosin
0.5647043204	apical
0.5647043204	conclude
0.5647043204	quetiapine
0.5647043204	orally
0.5647043204	defined
0.5647043204	unclear
0.5641799052	documented
0.5641014235	thirty
0.5640596488	combination
0.5639092514	agent
0.5630609648	pharmacological
0.5630609648	treatments
0.5630609648	cis
0.5630609648	cisplatin
0.5630609648	intrathecal
0.5630609648	inflammation
0.5630609648	terbutaline
0.5630609648	estimated
0.5630609648	secretion
0.5630609648	fluvoxamine
0.5630609648	untreated
0.5630609648	hypotensive
0.5630609648	s.c
0.5630609648	spontaneously
0.5630609648	volunteers
0.5630609648	basis
0.5630609648	levofloxacin
0.5630609648	stenosis
0.5630609648	selected
0.5630609648	designed
0.5630609648	areas
0.5630609648	disappeared
0.5630609648	play
0.5630609648	unknown
0.5630609648	presentation
0.5630609648	potentially
0.5630609648	region
0.5630609648	recommended
0.5630609648	complex
0.5630365733	spasm
0.5630365733	confirmed
0.5630365733	started
0.5630365733	locomotor
0.5630365733	maximum
0.5630365733	elevation
0.5630365733	pallidotomy
0.5630365733	monitored
0.5630365733	demonstrate
0.5630289181	purpose
0.5627395613	risk
0.5620469338	glaucoma
0.5620469338	recall
0.5620367345	long
0.5619903883	renal
0.5616489381	chf
0.5616340138	amlodipine
0.5615659769	achieved
0.5613689071	disease
0.5611888189	development
0.5609558549	rate
0.5608158454	increase
0.5605924085	clinical
0.5604464520	intake
0.5604464520	dosing
0.5604464520	ischemic
0.5602677607	micturition
0.5602677607	fold
0.5602677607	propofol
0.5600023387	administered
0.5599646113	perfusion
0.5598762196	features
0.5598762196	anesthetics
0.5598654717	eyes
0.5594763765	injection
0.5594688773	bp
0.5593683586	eps
0.5592802867	lidocaine
0.5592802867	excretion
0.5592302819	dopaminergic
0.5592302819	noted
0.5592302819	episodes
0.5590562473	related
0.5586303414	cardiac
0.5586015556	ra
0.5584526816	discussion
0.5584318637	reflex
0.5584318637	consumption
0.5584318637	wall
0.5584318637	protocol
0.5584318637	content
0.5583643394	mtdna
0.5583023674	cycle
0.5583023674	sites
0.5583023674	trihexyphenidyl
0.5583023674	cost
0.5583023674	antigens
0.5583023674	cholinesterase
0.5583023674	alfentanil
0.5582280212	nervous system
0.5575403117	result
0.5569723919	suggested
0.5569643162	control
0.5568376829	cm
0.5567502837	tdp
0.5565396774	contralateral
0.5565396774	zidovudine
0.5564553074	lesion
0.5562289593	meth
0.5561615591	target
0.5556603057	age
0.5552044303	dyskinesias
0.5551555581	frequently
0.5551555581	inhibited
0.5551555581	support
0.5551555581	ability
0.5551555581	maintenance
0.5551555581	detected
0.5550119868	csa
0.5549473067	wk
0.5548658977	prevented
0.5548658977	female
0.5548658977	commonly
0.5548658977	discontinued
0.5548658977	angiography
0.5548658977	completely
0.5548658977	induce
0.5545306381	inos
0.5544711075	determine
0.5544318757	evaluate
0.5543451771	partial
0.5542674462	myalgia
0.5542288135	study
0.5542081228	minutes
0.5540124986	vehicle
0.5539790244	iii
0.5539413077	alf
0.5539413077	pregs
0.5539296044	cs
0.5538195035	vip
0.5537122596	breast
0.5536251838	cimetidine
0.5533189115	med
0.5531844180	function
0.5530819784	obtained
0.5530819784	recorded
0.5528251017	samples
0.5527585273	iodixanol
0.5527585273	collected
0.5527585273	mmol
0.5527585273	segment
0.5527297077	dilevalol
0.5527297077	beta1
0.5527014228	treated rats
0.5525424035	hypercalcemia
0.5525424035	netilmicin
0.5525424035	pathological
0.5525424035	potentiated
0.5525424035	cyclosporine
0.5525424035	clearance
0.5525424035	alternative
0.5525424035	improves
0.5525424035	conditions
0.5525424035	metabolites
0.5525424035	occurs
0.5525424035	develop
0.5525424035	consisted
0.5525424035	ingestion
0.5525424035	younger
0.5525424035	outcomes
0.5525424035	applied
0.5525424035	pathogenesis
0.5525424035	distinct
0.5525424035	regions
0.5525424035	generalized
0.5525424035	idiopathic
0.5525424035	needed
0.5525424035	terms
0.5525424035	fixed
0.5525424035	differ
0.5525424035	schizophrenia
0.5525424035	reviewed
0.5525424035	focal
0.5525424035	procedures
0.5525424035	phenomenon
0.5525424035	represent
0.5525424035	observation
0.5525424035	returned
0.5525424035	morbidity
0.5525424035	derivative
0.5525424035	respect
0.5525424035	functions
0.5525424035	completed
0.5525424035	process
0.5525424035	pediatric
0.5525424035	bolus
0.5525424035	maintained
0.5525424035	starting
0.5525424035	child
0.5523921796	reported
0.5522496480	groups
0.5520360333	abnormal
0.5520360333	glutamate
0.5515472700	ci
0.5515329642	experienced
0.5515329642	hours
0.5514463325	threshold
0.5511752119	cyp
0.5511671630	sm
0.5511382880	resolution
0.5511382880	actions
0.5511382880	schedule
0.5511382880	methyl
0.5511382880	include
0.5511382880	markedly
0.5511382880	withdrawal
0.5511382880	provide
0.5511382880	cellular
0.5511382880	unchanged
0.5511382880	hypertrophy
0.5511382880	discussed
0.5511382880	pregnancy
0.5511382880	testosterone
0.5511382880	approach
0.5511382880	concluded
0.5511382880	form
0.5511382880	blocking
0.5511382880	indicating
0.5511382880	fed
0.5511382880	monotherapy
0.5511382880	beneficial
0.5511382880	survival
0.5511382880	manner
0.5511382880	affect
0.5511382880	remains
0.5511382880	consecutive
0.5511357841	hemolytic
0.5508398873	resolved
0.5508398873	movements
0.5508398873	improved
0.5508398873	underwent
0.5508398873	advanced
0.5508398873	exhibited
0.5508398873	conducted
0.5507477499	reversed
0.5507477499	identified
0.5507477499	rare
0.5507477499	shown
0.5506158151	abnormalities
0.5506158151	difference
0.5506158151	responses
0.5504584041	patient
0.5503854265	pd
0.5503817795	objectives
0.5503401829	reduction
0.5502907861	placebo
0.5501202369	active
0.5501202369	remained
0.5500315749	months
0.5499324818	rates
0.5499324818	range
0.5490485892	injected
0.5489933518	rubella
0.5483028497	parkinsonian
0.5482943549	pod
0.5482049907	min
0.5482011459	weeks
0.5475565608	pan
0.5475243866	den
0.5474713117	score
0.5471245709	oct
0.5469172970	nag
0.5468325745	shr
0.5466937992	ecg
0.5456629535	mdma
0.5455509548	medication
0.5455509548	affected
0.5455509548	parameters
0.5454847087	vpa
0.5453353773	evaluated
0.5452183642	reuptake
0.5452183642	accompanied
0.5452183642	humans
0.5452183642	treat
0.5452183642	failed
0.5451135370	values
0.5450365320	riha
0.5450304029	tested
0.5448584551	st
0.5447917176	reversal
0.5447917176	torsade
0.5447917176	oxidative
0.5447917176	fibrillation
0.5447152953	conclusion
0.5439225257	vitro
0.5439225257	appeared
0.5439225257	suggests
0.5437919913	results
0.5437717846	present
0.5435822208	considered
0.5435416861	rats
0.5434711097	stage
0.5434605366	subjects
0.5432863493	times
0.5431269205	cord
0.5430708183	parp
0.5430655453	studies
0.5428770545	gaba
0.5426265659	arrest
0.5424225039	dogs
0.5424225039	investigated
0.5419805799	dosage
0.5417814694	effect
0.5415134247	determined
0.5415134247	previously
0.5413248653	pb
0.5413248653	lid
0.5413186969	conclusions
0.5412926239	mice
0.5411828999	group
0.5410690128	increased
0.5408108033	controls
0.5405777671	mk
0.5404300386	neuroleptic
0.5403101317	infarction
0.5403101317	initiation
0.5402187358	week
0.5401874452	doses
0.5394713545	examined
0.5394186171	oab
0.5393291578	ntg
0.5391380130	adr
0.5390780632	iop
0.5390752480	report
0.5388603115	percent
0.5383184739	wt
0.5382887114	blind
0.5377473677	randomly assigned to
0.5374841723	healthy
0.5372893237	cases
0.5370650109	measured
0.5370650109	revealed
0.5370650109	performed
0.5359563945	agents
0.5359563945	included
0.5359028581	af
0.5359028581	sd
0.5355406962	stz
0.5355406962	gad
0.5348918343	dose
0.5348259273	dox
0.5325302041	toxic
0.5322605925	levels
0.5315593427	puromycin
0.5306305448	receptors
0.5304430826	demonstrated
0.5301871211	methods
0.5299842260	administration
0.5298375234	days
0.5292088745	toxicity
0.5291540347	including
0.5282491323	treatment
0.5277691710	bis
0.5260148027	effects
0.5245951805	seizures
0.5244196441	observed
0.5218884351	cp
0.5212833566	developed
0.5211394960	saline
0.5208933082	compared
0.5207700671	patients
0.5201223790	normal
0.5200687148	significantly
0.5187006901	assess
0.5169592604	decreased
0.5156233775	period
0.5151987899	group ii
0.5128641399	activity
0.5122568220	therapy
0.5107729066	mg
0.5092939220	alpha
0.5084036785	treated
0.5081801799	years
0.5079955363	number
0.5068627744	follow
0.5049032757	vitamin c
0.5041885967	term
0.5039933317	kg
0.4990902524	d penicillamine
0.4977554547	hepatitis b
0.4976272275	received
0.4956039810	showed
0.4875166463	patients undergoing
0.4859196940	95 confidence interval
0.4854355022	significantly reduced
0.4761799011	5 fu
0.4739652062	induced
0.4700329347	x
0.4698675872	right
0.4697778696	levodopa induced
0.4648909461	follow up
0.4628659692	lithium therapy
0.4537743738	95 ci
0.4489807585	second
0.4483443457	de pointes
0.4476462754	results suggest
0.4456826078	novel
0.4456408010	value
0.4318936943	48
0.4307910179	does
0.4257402470	twice
0.4226650229	last
0.4225655478	first
0.4193357620	m
0.4117377345	such
0.4105254583	new
0.4104109504	de
0.4098024045	seems
0.4091610850	t
0.4067601588	h
0.4054300482	possible
0.4025844635	most
0.4020876513	200
0.3966200553	0.01
0.3956634343	80
0.3956116240	side effects
0.3955868183	b
0.3952747071	seen
0.3923250797	throughout
0.3923250797	taken
0.3920478117	five
0.3902872222	her
0.3886250145	c
0.3885500468	overall
0.3869335992	n
0.3868117581	various
0.3844766077	eight
0.3838491942	until
0.3837475271	serious
0.3824159943	followed
0.3817748586	0.001
0.3807262498	his
0.3807262498	therefore
0.3807092701	l
0.3806503833	indicate
0.3802454983	95 confidence
0.3801558484	course
0.3799948430	they
0.3798296238	little
0.3788156129	co
0.3768062303	system
0.3758349854	twice daily
0.3750061138	d
0.3748505814	old
0.3747439236	95
0.3741878555	corresponding
0.3740634920	another
0.3740634920	many
0.3732446774	cause
0.3730739843	none
0.3720475217	ten
0.3720475217	she
0.3718941720	acute liver
0.3715862087	side
0.3713588118	sixty
0.3700095683	did
0.3699412028	he
0.3698795980	per
0.3697722556	further
0.3692750636	six
0.3688634883	four
0.3683211013	p
0.3681370380	14
0.3680955894	24
0.3672479561	several
0.3670949466	because
0.3670012876	third
0.3668987871	well tolerated
0.3668779040	well
0.3668744156	following
0.3660067151	0.05
0.3659147076	among
0.3658037598	off
0.3657657904	neither
0.3657491390	nine
0.3652678705	since
0.3652496586	seven
0.3649674966	despite
0.3648286623	least
0.3645354825	5 ht
0.3636298762	associated
0.3634738127	found
0.3627097995	year
0.3611725840	0.5
0.3610282400	if
0.3609780861	within
0.3609544584	here
0.3605373129	100
0.3603551770	=
0.3599930081	s
0.3593624267	even
0.3585886208	50
0.3581049292	7
0.3579671778	less
0.3578164074	few
0.3578164074	often
0.3577016860	some
0.3571856690	three
0.3570479375	the present study
0.3564222001	both
0.3555871115	very
0.3555871115	above
0.3551857395	thus
0.3544618504	forty
0.3543522378	before
0.3538183931	same
0.3534097786	due
0.3520633075	up
0.3515924949	r
0.3504335177	g
0.3493899241	furthermore
0.3492205035	moreover
0.3479091461	twenty
0.3473312624	changes
0.3468968114	time
0.3468960519	mean
0.3464920271	30
0.3458814010	i
0.3456499454	while
0.3455567538	other
0.3455066161	use
0.3448214331	24 hour
0.3442271844	our
0.3437378291	out
0.3435617260	at
0.3429805913	after
0.3422805176	one
0.3410705401	greater than
0.3405170727	so
0.3405170727	via
0.3405170727	available
0.3404367897	more
0.3398848961	whereas
0.3398568893	using
0.3397383661	two
0.3378095821	this
0.3372520255	a significant decrease
0.3368692667	20
0.3354131957	e
0.3351766793	although
0.3349877067	k
0.3330846251	0.2
0.3325072268	when
0.3318106551	31
0.3316315072	all
0.3316211647	than
0.3311306427	day
0.3311304749	an
0.3309353038	a
0.3308385451	as
0.3307892714	41
0.3307892714	67
0.3304647609	in
0.3300560449	35
0.3297199581	used
0.3294470070	29
0.3292427312	these
0.3288717746	between
0.3284520845	150
0.3284520845	0.3
0.3276944622	57
0.3269169110	32
0.3261649090	33
0.3261457840	the
0.3261444557	relatively
0.3261444557	801
0.3261444557	probably
0.3261444557	where
0.3261444557	120
0.3261444557	necessary
0.3261444557	particularly
0.3261436496	12
0.3253559703	250
0.3252712670	23
0.3252712670	45
0.3252395335	however
0.3250624047	on
0.3247170481	no
0.3246209065	almost
0.3246209065	0.6
0.3245622873	6
0.3243248716	whom
0.3243248716	better
0.3242385010	significantly increased
0.3238812663	each
0.3231478171	their
0.3230464571	3.8
0.3230464571	would
0.3230464571	300
0.3230464571	need
0.3230464571	clearly
0.3230464571	done
0.3227023207	to
0.3226125494	there
0.3225811312	side effect
0.3219755518	10
0.3214323141	under
0.3214323141	any
0.3211902702	but
0.3198044813	it
0.3197850985	every
0.3197850985	once
0.3187100217	during
0.3183949545	of
0.3182868480	relationship between
0.3181064105	over
0.3181020404	2.0
0.3179635556	from
0.3179339003	26
0.3175661467	by
0.3173257883	still
0.3173257883	mainly
0.3173257883	made
0.3172789807	whether
0.3170638868	not
0.3167966165	16
0.3163499923	nor
0.3163499923	indicated
0.3143165008	with
0.3141392176	65
0.3141392176	27
0.3141392176	then
0.3141392176	being
0.3140788811	22
0.3131439604	through
0.3128196716	given
0.3114669222	likely
0.3113252995	1
0.3111226642	1.5
0.3111019781	those
0.3107986801	19
0.3107840313	non
0.3104487850	patient developed
0.3103556815	18
0.3103556815	containing
0.3103556815	causes
0.3102078313	about
0.3095864613	for
0.3089011361	2.5
0.3087739355	90
0.3087739355	part
0.3087739355	might
0.3087739355	useful
0.3085395409	we
0.3082864705	17
0.3081424549	known
0.3081193900	500
0.3080236256	13
0.3079041630	5
0.3073145952	p 0.05
0.3066751859	3
0.3061000141	especially
0.3058493670	25
0.3055439801	40
0.3047809743	+
0.3044883847	plus
0.3044883847	show
0.3035407306	0
0.3034323950	1.0
0.3027666808	later
0.3027666808	describe
0.3027666808	0.1
0.3007660910	year old woman
0.2992732543	4
0.2980237633	2
0.2965304888	could
0.2958678729	vs
0.2953401387	11
0.2947011464	21
0.2946521446	alone
0.2945304888	different
0.2938868963	9
0.2932292271	its
0.2916849771	should
0.2913886830	or
0.2910297876	60
0.2906094389	like
0.2904489847	15
0.2901342446	8
0.2897946909	0.5 microl
0.2896682884	either
0.2891596612	against
0.2889992671	these results suggest
0.2882947741	respectively
0.2876807075	also
0.2873665335	described
0.2869929946	into
0.2855045891	48 h
0.2840820145	without
0.2829598971	year old
0.2811374186	can
0.2807846937	old woman
0.2802455812	only
0.2774481275	n =
0.2766754242	200 mg
0.2744752780	single dose
0.2742971311	widely used
0.2699483166	has
0.2699483166	which
0.2689483166	who
0.2674413576	elderly patients
0.2674218663	and
0.2669483166	have
0.2669483166	been
0.2643341699	had
0.2643341699	may
0.2643341699	are
0.2638070307	s disease
0.2612764878	be
0.2608479164	that
0.2608479164	was
0.2608479164	were
0.2608479164	is
0.2600993327	p 0.001
0.2574854179	responsible for
0.2532283851	x 10
0.2524241163	p 0.01
0.2519755304	as well as
0.2475821272	year old man
0.2472820160	induced convulsions
0.2467386900	mg m
0.2389045974	kg i.v
0.2354356887	the placebo group
0.2345314507	the most common
0.2337495237	regulation of
0.2309202693	min before
0.2269294008	100 mg
0.2266973362	did not
0.2226241661	80 mg
0.2199364576	differences between
0.2159152066	0.5 mg
0.2154326523	7 days
0.2153925832	association between
0.2146975834	does not
0.2141602134	able to
0.2129575574	compared with
0.2122611245	on pod
0.2122604791	old man
0.2113126304	patients receiving
0.2109747518	assigned to
0.2102347368	p =
0.2079565466	haloperidol induced
0.2078519909	heparin induced
0.2073530147	24 h
0.2066409684	an important
0.2056017216	at least
0.2026354998	in order to
0.2018942044	a single dose
0.2012964966	p less than
0.2006434920	these findings
0.1972290370	acute renal
0.1944350968	14 days
0.1939419543	characterized by
0.1928609497	results indicate
0.1914310852	induced hypotension
0.1888303926	treated patients
0.1874837692	present study
0.1815078324	according to
0.1805356443	mg day
0.1798398572	based on
0.1783594264	drug induced
0.1783147988	the presence of
0.1767711389	due to
0.1736398317	time course
0.1723909001	a case report
0.1708877287	to assess
0.1692758529	such as
0.1689464008	the presence
0.1676339653	control group
0.1675453258	mean arterial
0.1675143883	no evidence
0.1674774864	30 min
0.1665358375	to evaluate
0.1654407934	accompanied by
0.1638752168	patients treated
0.1611312738	doxorubicin induced
0.1552073448	consistent with
0.1543315206	both groups
0.1538560623	associated with
0.1537625569	less than 0.05
0.1498645917	patients developed
0.1495596470	to determine
0.1487396664	group b
0.1471574446	6 weeks
0.1458878828	failed to
0.1453950162	to treat
0.1449010174	pretreated with
0.1436557762	the occurrence of
0.1435781465	in combination with
0.1432575008	caused by
0.1416347083	placebo group
0.1404098972	no significant
0.1385874001	the aim of
0.1385527177	a dose dependent
0.1378839075	two groups
0.1376548657	the control group
0.1347142713	higher than
0.1322266170	immediately after
0.1309721690	led to
0.1308041624	an average
0.1261448533	induced catalepsy
0.1240811084	per day
0.1236188909	in patients receiving
0.1227882824	to investigate
0.1202808122	treated with
0.1189485414	patients treated with
0.1177520342	initiation of
0.1171463567	10 mg kg
0.1158048115	number of
0.1151812993	this study
0.1136315421	mg per
0.1135550961	50 mg kg
0.1094420275	50 mg
0.1077617327	appears to
0.1072212120	the long term
0.1067693195	1 mg kg
0.1031035293	less than
0.1022912074	seems to
0.1011983050	in humans
0.0999748019	the same
0.0983935145	reversal of
0.0977763294	20 mg
0.0974503871	induced by
0.0939015333	both drugs
0.0921170400	these data
0.0883289456	followed by
0.0881993761	but not
0.0854851173	single dose of
0.0853591341	the striatum
0.0846087509	no effect on
0.0839276784	5 mg
0.0832296764	5 mg kg
0.0787775103	these results
0.0783184080	resulted in
0.0778301384	a case of
0.0757971210	patients with
0.0727850254	one patient
0.0727414872	in patients with
0.0707872813	the development of
0.0699301384	a patient with
0.0693367687	before and after
0.0691360955	a novel
0.0673419232	two cases of
0.0664122953	administration of
0.0658645987	t +
0.0656605581	this patient
0.0633630749	the effect of
0.0630461707	all patients
0.0630301384	the treatment of
0.0625083298	correlated with
0.0620464391	compared to
0.0618190273	the incidence of
0.0607297416	the effects of
0.0602330101	more than
0.0596830866	produced by
0.0590301384	the use of
0.0576903028	effects of
0.0563679239	doses of
0.0554617284	the role of
0.0553885597	an increase in
0.0553434246	treatment with
0.0551681734	mediated by
0.0542835981	the patient
0.0535446327	10 mg
0.0535029957	two cases
0.0517305625	effect of
0.0507113943	in rats
0.0497950617	the efficacy and
0.0496395061	the number of
0.0496061728	the absence of
0.0489639132	to receive
0.0485793921	secondary to
0.0484617284	a history of
0.0481966405	a total of
0.0473094990	increase in
0.0472980619	the procedure
0.0464276251	an effective
0.0463688742	related to
0.0444073548	the risk of
0.0441105439	implicated in
0.0437878697	effect on
0.0436901779	dose of
0.0419427428	an increase
0.0413690455	the literature
0.0407950617	the onset of
0.0407251865	the administration of
0.0404617284	the results of
0.0394617284	the duration of
0.0387585198	of treatment with
0.0374986214	the last
0.0369711033	at doses
0.0369586776	association with
0.0368251865	of patients with
0.0362623658	assessed by
0.0362150790	women on
0.0357143415	presented with
0.0354580350	response to
0.0351717305	days after
0.0349371696	the study
0.0343885381	a phase
0.0343171186	neurons in
0.0339410780	decrease in
0.0337366633	the brain
0.0331924887	the rat
0.0331826418	no effect
0.0327366633	the development
0.0322189483	these patients
0.0311608030	30 mg
0.0310353330	the current
0.0309895682	at risk
0.0307626276	children with
0.0307366633	a case
0.0307159751	not significantly
0.0304388914	this case
0.0300371696	in mice
0.0299245605	action of
0.0295840411	change in
0.0293937768	or more
0.0292520920	aware of
0.0291636910	cells in
0.0291636910	days of
0.0289875057	effects on
0.0288728633	prior to
0.0287699966	the number
0.0286511116	rise in
0.0285941358	a single
0.0284878063	absence of
0.0283045120	the drug
0.0281327891	discontinuation of
0.0281203271	combined with
0.0280103506	inhibition of
0.0277971219	cases of
0.0275811414	risk for
0.0275617904	five patients
0.0275410780	injection of
0.0272808320	degree of
0.0272746338	the first
0.0271366633	the control
0.0271366633	the present
0.0267966092	pretreatment with
0.0267680780	h after
0.0267254656	increased from
0.0260947855	severity of
0.0259427428	four patients
0.0259276905	course of
0.0257742524	the hypothesis
0.0257498464	history of
0.0256818732	three patients
0.0249589821	an acute
0.0248967494	treatment for
0.0248633792	involved in
0.0245320309	improvement in
0.0242795204	the combined
0.0242795204	the effect
0.0242275596	reduction in
0.0240742524	a prospective
0.0237185997	case of
0.0235636910	activity in
0.0233746338	changes in
0.0230276686	the aim
0.0230137718	exposure to
0.0228369086	prevention of
0.0226971219	observed in
0.0223245605	onset of
0.0223073215	evaluation of
0.0220337251	in patients
0.0218485399	2 mg
0.0217204252	development of
0.0214959480	this drug
0.0213795204	in animals
0.0213795204	the results
0.0213795204	the kidney
0.0212189483	3 patients
0.0212102338	1 mg
0.0209358929	incidence of
0.0208125066	levels of
0.0208054696	increases in
0.0207737781	loss of
0.0204078939	activation of
0.0202786032	failure in
0.0202736241	two patients
0.0200678257	model of
0.0199129833	woman with
0.0198882739	duration of
0.0197876209	frequency of
0.0197015738	a significant
0.0195364220	management of
0.0188615262	treatment of
0.0186936775	patient with
0.0186376209	assessment of
0.0186376209	alterations in
0.0185320309	involvement of
0.0183795204	in women
0.0183786032	results of
0.0183786032	studies of
0.0181394728	activity of
0.0180510890	evidence of
0.0179328079	patients on
0.0179328079	rats with
0.0177885381	a history
0.0177876209	models of
0.0176542876	diagnosis of
0.0173795204	the duration
0.0173786032	weeks of
0.0173073215	expression of
0.0172948595	similar to
0.0172876209	differences in
0.0171394728	effective in
0.0170276686	in vivo
0.0170132739	reduction of
0.0168767514	occurrence of
0.0168091576	use of
0.0167876209	injections of
0.0166936775	administered to
0.0164800495	a specific
0.0163795204	a patient
0.0163795204	the potential
0.0163786032	months of
0.0163786032	function in
0.0163786032	report of
0.0163073215	role of
0.0163073215	role in
0.0162823299	reported to
0.0161394728	trial of
0.0161394728	mechanism of
0.0161394728	combination of
0.0161394728	expression in
0.0160276686	the protective
0.0160276686	a selective
0.0158540081	a new
0.0157936775	women with
0.0157936775	mice with
0.0157936775	therapy for
0.0157936775	therapy with
0.0155461871	the incidence
0.0155000766	a double
0.0153795204	a group
0.0153795204	in children
0.0153795204	the combination
0.0153073215	induction of
0.0153073215	rate of
0.0153073215	occurred in
0.0153073215	risk of
0.0151394728	concentration of
0.0151394728	review of
0.0151394728	end of
0.0151394728	infusion of
0.0151394728	efficacy of
0.0151394728	type of
0.0151394728	concentrations of
0.0151394728	level of
0.0151394728	studied in
0.0151394728	present in
0.0151394728	toxicity of
0.0150276686	a total
0.0147652881	the right
0.0147392070	the occurrence
0.0143795204	a low
0.0143795204	the risk
0.0143795204	the mechanism
0.0143786032	increase of
0.0143786032	administered in
0.0141394728	symptoms of
0.0141394728	mechanisms of
0.0141394728	analysis of
0.0141394728	reported in
0.0140267514	combination with
0.0140267514	aim of
0.0139705561	the time
0.0130910589	to control
0.0128926094	found to
0.0123812619	found in
0.0123729089	used for
0.0117247607	used to
0.0117187042	seen in
0.0117187042	day for
0.0117187042	up to
0.0117187042	the second
0.0115282280	a possible
0.0112384048	cause of
0.0112384048	the other
0.0110705561	time of
0.0110619342	the mean
0.0100705561	used in
0.0100705561	the most
0.0100705561	the possible
